Indian Journal of Respiratory Care

IJRC Email      Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  13 (2024)
Volume  12 (2023)
Volume  11 (2022)
Volume  10 (2021)
Volume  9 (2020)
Volume  8 (2019)
Volume  7 (2018)
Volume  6 (2017)
Volume  5 (2016)
Volume  4 (2015)
Volume  3 (2014)
Volume  2 (2013)
Volume  1 (2012)
Related articles

VOLUME 13 , ISSUE 1 ( January-March, 2024 ) > List of Articles

REVIEW ARTICLE

Immunoprophylaxis of Respiratory Syncytial Virus Infection: Recent Updates

Nuzhat Umran, Prabu Dhandapani

Keywords : Antiviral, Developing countries, Immune response, Respiratory syncytial virus, Vaccine, Viral pathogenesis

Citation Information : Umran N, Dhandapani P. Immunoprophylaxis of Respiratory Syncytial Virus Infection: Recent Updates. Indian J Respir Care 2024; 13 (1):43-49.

DOI: 10.5005/jp-journals-11010-1087

License: CC BY-NC 4.0

Published Online: 06-04-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

The respiratory syncytial virus (RSV) has been the most prevalent cause of respiratory illness in children and infants. Although the humoral immune response usually produces anti-RSV neutralizing antibodies during an infant's initial infection, they are usually insufficient. Despite the fact that RSV-specific neutralizing antibody production remains effective during infection, humoral immunity declines with time, resulting in frequent reinfection in subsequent seasons. With high prevalence and significant morbidity in young children and older adults, currently available patient care for RSV is based on supportive therapy. RSV prevention strategies have advanced significantly as a result of ongoing studies on the immunopathology, community transmission, and mechanisms underlying the virus replication. Despite the fact that RSV and poliovirus were discovered at the same time, cost-effective vaccinations for the risk groups were unavailable in many countries.

PDF Share
  1. McLaughlin JM, Khan F, Begier E, et al. Rates of medically attended RSV among US adults: a systematic review and meta-analysis. Open Forum Infect Dis 2022;9(7):ofac300. DOI: 10.1093/ofid/ofac300
  2. Battles MB, McLellan JS. Respiratory syncytial virus entry and how to block it. Nat Rev Microbiol 2019;17(4):233–245. DOI: 10.1038/s41579-019-0149-x
  3. Bergeron HC, Tripp RA. Immunopathology of RSV: An Updated Review. Viruses 2021;13(12): DOI: 10.3390/v13122478
  4. Kiss G, Holl JM, Williams GM, et al. Structural analysis of respiratory syncytial virus reveals the position of M2-1 between the matrix protein and the ribonucleoprotein complex. J Virol 2014;88(13):7602–7617. DOI: 10.1128/JVI.00256-14
  5. Carvajal JJ, Avellaneda AM, Salazar-Ardiles C, et al. Host components contributing to respiratory syncytial virus pathogenesis. Front Immunol 2019;10:2152. DOI: 10.3389/fimmu.2019.02152
  6. Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 2017;390(10098):946–958. DOI: 10.1016/S0140-6736(17)30938-8
  7. Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev 2014;35(12):519–530. DOI: 10.1542/pir.35-12-519
  8. Li L, Wang H, Liu A, et al. Age-dependent clinical characteristics of acute lower respiratory infections in young hospitalized children with respiratory syncytial virus infection. Infect Drug Resist 2022;15:5971–5979. DOI: 10.2147/IDR.S380681
  9. RSV (Respiratory Syncytial Virus) | CDC. (n.d.). Retrieved 7 September, 2023, fromhttps://www.cdc.gov/rsv/index.html
  10. Respiratory syncytial virus (RSV): diagnosis & treatment - Mayo Clinic. (n.d.). Retrieved 7 September 2023, fromhttps://www.mayoclinic.org/diseases-conditions/respiratory-syncytial-virus/diagnosis-treatment/drc-20353104
  11. Symptoms and Care of RSV (Respiratory Syncytial Virus) | CDC. (n.d.). Retrieved 7 September 2023, fromhttps://www.cdc.gov/rsv/about/symptoms.html
  12. Carbonell-Estrany X, Rodgers-Gray BS, Paes B. Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries. Expert Rev Anti Infect Ther 2021;19(4):419–441. DOI: 10.1080/14787210.2021.1828866
  13. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2095–2128. DOI: 10.1016/S0140-6736(12)61728-0
  14. Larrañaga CL, Ampuero SL, Luchsinger VF, et al. Impaired immune response in severe human lower tract respiratory infection by respiratory syncytial virus. Pediatr Infecti Dis J 2009;28(10):867–873. DOI: 10.1097/INF.0b013e3181a3ea7
  15. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 2000;13(3):371–384. DOI: 10.1128/CMR.13.3.371
  16. Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005;352(17):1749–1759. DOI: 10.1056/NEJMoa043951
  17. Falsey AR, Walsh EE. Respiratory syncytial virus infection in elderly adults. Drugs Aging 2005;22(7):577–587. DOI: 10.2165/00002512-200522070-00004
  18. Jafri HS, Chavez-Bueno S, Mejias A, et al. Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice. J Infect Dis 2004;189(10):1856–1865. DOI: 10.1086/386372
  19. Liu B, Kimura Y. Local immune response to respiratory syncytial virus infection is diminished in senescence-accelerated mice. J Gen Virol 2007;88(Pt 9):2552–2558. DOI: 10.1099/vir.0.83089-0
  20. Bianchini S, Silvestri E, Argentiero A, et al. Role of respiratory syncytial virus in pediatric pneumonia. Microorganisms 2020;8(12): DOI: 10.3390/microorganisms8122048
  21. McNamara PS, Flanagan BF, Hart CA, et al. Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis. J Infect Dis 2005;191(8):1225–1232. DOI: 10.1086/428855
  22. Saravia J, You D, Shrestha B, et al. Respiratory syncytial virus disease is mediated by age-variable IL-33. PLoS Pathog 2015;11(10):e1005217. DOI: 10.1371/journal.ppat.1005217
  23. Duvvuri VR, Granados A, Rosenfeld P, et al. Genetic diversity and evolutionary insights of respiratory syncytial virus A ON1 genotype: global and local transmission dynamics. Sci Rep 2015;5:14268. DOI: 10.1038/srep14268
  24. Noor A, Krilov LR. Respiratory syncytial virus vaccine: where are we now and what comes next? Expert Opin Biol Ther 2018;18(12):1247–1256. DOI: 10.1080/14712598.2018.1544239
  25. Niewiesk S. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol 2014;5:446. DOI: 10.3389/fimmu.2014.00446
  26. Basha S, Surendran N, Pichichero M. Immune responses in neonates. Expert Rev Clin Immunol 2014;10(9):1171–1184. DOI: 10.1586/1744666X.2014.942288
  27. Schmidt ME, Meyerholz DK, Varga SM. Pre-existing neutralizing antibodies prevent CD8 T cell-mediated immunopathology following respiratory syncytial virus infection. Mucosal Immunol 2020;13(3):507–517. DOI: 10.1038/s41385-019-0243-4
  28. Sigurs N. Epidemiologic and clinical evidence of a respiratory syncytial virus-reactive airway disease link. Am J Respir Crit Care Med 2001;163(3 Pt 2):S2–S6. DOI: 10.1164/ajrccm.163.supplement_1.2011109
  29. Domachowske JB, Rosenberg HF. Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Clin Microbiol Rev 1999;12(2):298–309. DOI: 10.1128/CMR.12.2.298
  30. Taleb SA, Al Thani AA, Al Ansari K, et al. Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches. Eur J Clin Microbiol Infect Dis 2018;37(10):1817–1827. DOI: 10.1007/s10096-018-3289-4
  31. Green CA, Sande CJ, de Lara C, et al. Humoral and cellular immunity to RSV in infants, children and adults. Vaccine 2018;36(41):6183–6190. DOI: 10.1016/j.vaccine.2018.08.056
  32. Mukherjee S, Lindell DM, Berlin AA, et al. IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. Am J Pathol 2011;179(1):248–258. DOI: 10.1016/j.ajpath.2011.03.003
  33. Schmidt ME, Varga SM. Cytokines and CD8 T cell immunity during respiratory syncytial virus infection. Cytokine 2020;133:154481. DOI: 10.1016/j.cyto.2018.07.012
  34. Bertuzzi M, Hayes GE, Bignell EM. Microbial uptake by the respiratory epithelium: outcomes for host and pathogen. FEMS Microbiol Rev 2019;43(2):145–161. DOI: 10.1093/femsre/fuy045
  35. Janet S, Broad J, Snape MD. Respiratory syncytial virus seasonality and its implications on prevention strategies. Hum Vaccin Immunother 2018;14(1):234–244. DOI: 10.1080/21645515.2017.1403707
  36. Eiland LS. Respiratory syncytial virus: diagnosis, treatment and prevention. J Pediatr Pharmacol Ther 2009;14(2):75–85. DOI: 10.5863/1551-6776-14.2.75
  37. Modjarrad K, Giersing B, Kaslow DC, et al. WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization meeting held on 23-24 March 2015. Vaccine 2016;34(2):190–197. DOI: 10.1016/j.vaccine.2015.05.093
  38. Legand A, Briand S, Shindo N, et al. Addressing the public health burden of respiratory viruses: the battle against respiratory viruses (BRaVE) initiative. Future Virol 2013;8(10):953–968. DOI: 10.2217/fvl.13.85
  39. Gatt D, Martin I, AlFouzan R, et al. Prevention and treatment strategies for respiratory syncytial virus (RSV). Pathogens 2023;12(2). DOI: 10.3390/pathogens12020154
  40. Bont L, Versteegh J, Swelsen WT, et al. Natural reinfection with respiratory syncytial virus does not boost virus-specific T-cell immunity. Pediatr Res 2002;52(3):363–367. DOI: 10.1203/00006450-200209000-00009
  41. Castilow EM, Olson MR, Varga SM. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol Res 2007;39(1-3):225–239. DOI: 10.1007/s12026-007-0071-6
  42. Openshaw PJ, Culley FJ, Olszewska W. Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 2001;20 Suppl 1:S27–S31. DOI: 10.1016/S0264-410X(01)00301-2
  43. Mazur NI, Terstappen J, Baral R, et al. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis 2023;23(1):e2–e21. DOI: 10.1016/S1473-3099(22)00291-2
  44. Mazur NI, Higgins D, Nunes MC, et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis 2018;18(10):e295–e311. DOI: 10.1016/S1473-3099(18)30292-5
  45. Mejias A, Rodríguez-Fernández R, Oliva S, et al. The journey to a respiratory syncytial virus vaccine. Ann Allergy Asthma Immunol 2020;125(1):36–46. DOI: 10.1016/j.anai.2020.03.017
  46. Garegnani L, Styrmisdóttir L, Roson Rodriguez P, et al. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev 2021;11(11):CD013757. DOI: 10.1002/14651858.CD013757.pub2
  47. FDA Approves New Drug to Prevent RSV in Babies and Toddlers | FDA. (n.d.). Retrieved 7 September 2023, fromhttps://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers
  48. Sáez-Llorens X, Moreno MT, Ramilo O, et al. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J 2004;23(8):707–712. DOI: 10.1097/01.inf.0000133165.85909.08
  49. Ventre K, Randolph AG. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2007;(1):CD000181. DOI: 10.1002/14651858.CD000181.pub3
  50. Boeckh M, Englund J, Li Y, et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2007;44(2):245–249. DOI: 10.1086/509930
  51. Sinclair SM, Jones JK, Miller RK, et al. The ribavirin pregnancy registry: an interim analysis of potential teratogenicity at the mid-point of enrollment. Drug Saf 2017;40(12):1205–1218. DOI: 10.1007/s40264-017-0566-6
  52. Shults RA, Baron S, Decker J, et al. Health care worker exposure to aerosolized ribavirin: biological and air monitoring. J Occup Environ Med 1996;38(3):257–263. DOI: 10.1097/00043764-199603000-00010
  53. Tejada S, Martinez-Reviejo R, Karakoc HN, et al. Ribavirin for treatment of subjects with respiratory syncytial virus-related infection: a systematic review and meta-analysis. Adv Ther 2022;39(9):4037–4051. DOI: 10.1007/s12325-022-02256-5
  54. Simões EA, DeVincenzo JP, Boeckh M, et al. Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis 2015;211(Suppl 1):S1–S20. DOI: 10.1093/infdis/jiu828
  55. Biagi C, Dondi A, Scarpini S, et al. Current state and challenges in developing respiratory syncytial virus vaccines. Vaccines (Basel) 2020;8(4). DOI: 10.3390/vaccines8040672
  56. Srikantiah P, Vora P, Klugman KP. Assessing the full burden of respiratory syncytial virus in young infants in low- and middle-income countries: the importance of community mortality studies. Clin Infect Dis 2021;73(Suppl_3):S177–S179. DOI: 10.1093/cid/ciab486
  57. Efstathiou C, Abidi SH, Harker J, et al. Revisiting respiratory syncytial virus's interaction with host immunity, towards novel therapeutics. Cell Mol Life Sci 2020;77(24):5045–5058. DOI: 10.1007/s00018-020-03557-0
  58. Slifka MK, Amanna IJ. Passive Immunization. Plotkin's Vaccines. 2018:84–95.e10. DOI: 10.1016/B978-0-323-35761-6.00008-0
  59. Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 2011;239(1):149–166. DOI: 10.1111/j.1600-065X.2010.00972.x
  60. Berbers G, Mollema L, van der Klis F, et al. Antibody responses to respiratory syncytial virus: a cross-sectional serosurveillance study in the Dutch population focusing on infants younger than 2 years. J Infect Dis 2021;224(2):269–278. DOI: 10.1093/infdis/jiaa483
  61. Resch B. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Hum Vaccin Immunother 2017;13(9):2138–2149. DOI: 10.1080/21645515.2017.1337614
  62. Awosika AO, Patel P. Respiratory Syncytial Virus Prefusion F (RSVPreF3) vaccine. (Updated 2023 17 August). In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2023.
  63. Simon S, Joean O, Welte T, et al. The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus. Eur Respir Rev 2023;32(169). DOI: 10.1183/16000617.0034-2023
  64. Papi A, Ison MG, Langley JM, et al. Respiratory syncytial virus prefusion f protein vaccine in older adults. N Engl J Med 2023;388(7):595–608. DOI: 10.1056/NEJMoa2209604
  65. Shang Z, Tan S, Ma D. Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies. Int J Biol Sci 2021;17(14):4073–4091. DOI: 10.7150/ijbs.64762
  66. Peebles RS Jr, Graham BS. Pathogenesis of respiratory syncytial virus infection in the murine model. Proc Am Thorac Soc 2005;2(2):110–115. DOI: 10.1513/pats.200501-002AW
  67. Malik S, Ahmad T, Muhammad K, et al. Respiratory syncytial virus infection: treatments and clinical management. Vaccines (Basel) 2023;11(2). DOI: 10.3390/vaccines11020491
  68. Ouyang Y, Liao H, Hu Y, et al. Innate immune evasion by human respiratory syncytial virus. Front Microbiol 2022;13:865592. DOI: 10.3389/fmicb.2022.865592
  69. Johnson TR, Rao S, Seder RA, et al. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity. Vaccine 2009;27(23):3045–3052. DOI: 10.1016/j.vaccine.2009.03.026
  70. Ludlow M. Respiratory syncytial virus infection in the modern era. Curr Opin Infect Dis 2023;36(3):155–163. DOI: 10.1097/QCO.0000000000000917
  71. Anderson LJ, Dormitzer PR, Nokes DJ, et al. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine 2013;31 Suppl 2(Suppl 2):B209–B215. DOI: 10.1016/j.vaccine.2012.11.106
  72. Higgins D, Trujillo C, Keech C. Advances in RSV vaccine research and development - a global agenda. Vaccine 2016;34(26):2870–2875. DOI: 10.1016/j.vaccine.2016.03.109
  73. Jain H, Schweitzer JW, Justice NA. Respiratory Syncytial Virus Infection. (Updated 2022 8 November). In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2023.
  74. Carbonell-Estrany X, Simões EA, Bont LJ, et al. Prioritising respiratory syncytial virus prevention in low-income and middle-income countries. Lancet Glob Health 2023;11(5):e655–e657. DOI: 10.1016/S2214-109X(23)00165-1
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.